The financials
NovoCure Limited by the numbers
NovoCure Limited (NVCR) reported revenue of $174M in Q1 2026 (quarter ended March 31, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 78% and net loss of $71M. For the full year FY2025, revenue was $655M (+8.3% year on year) and net income −$136M. Its largest region in 2026-Q2 was United States at $103M, 62% of the disclosed total, just ahead of Germany at 14%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $174M | $155M | +12% |
| Gross profit | $135M | $116M | +16% |
| Operating income | −$67M | −$38M | n/a |
| Net income | −$71M | −$34M | n/a |
| Diluted EPS | −$0.62 | −$0.31 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $103M | 62% |
| Germany | $23M | 14% |
| France | $21M | 13% |
| Japan | $12M | 7.1% |
| China | $6.0M | 3.6% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q2 2026Total $165.4M (+4.4%)
China grew +30% year on yearUnited States +9.2% year on year
Segment Latestquarter on quarteryear on year
- United States$103.0M$103.0MQoQ +7.3%year on year +9.2%+7.3%+9.2%
- Germany$23.3M$23.3MQoQ -4.7%year on year +22%-4.7%+22%
- France$21.3M$21.3MQoQ -6.7%year on year +16%-6.7%+16%
- Japan$11.8M$11.8MQoQ +15%year on year +24%+15%+24%
- China$6.0M$6.0MQoQ +24%year on year +30%+24%+30%